Back to top

Ligand price target raised to $345 from $330 at Craig-Hallum

Craig-Hallum analyst Matt Hewitt raised the firm’s price target on Ligand (LGND) to $345 from $330 and keeps a Buy rating on the shares. Following ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ligand Pharmaceuticals Incorporated (LGND)

Palvella Therapeutics, Inc. (PVLA)

Banco Santander, S.A. (SAN)

Sanofi (SNY)